Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclin-dependent kinase inhibitors.

Yun Dai1, Steven Grant

  • 1Division of Hematology/Oncology, Medical College of Virginia, Virginia Commonwealth University, MCV Station Box 230, Richmond, VA 23298, USA

Current Opinion in Pharmacology
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The STEPs educational framework for medicines management: using mnemonics to reduce harm.

British journal of nursing (Mark Allen Publishing)·2026
Same author

Proteasome inhibition enhances lysosome-mediated targeted protein degradation.

Cell death & disease·2026
Same author

Hypochlorous Acid-Gated Hydrolysis of a Phosphinate Ester Dye in Living Cells.

Journal of the American Chemical Society·2025
Same author

Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines.

British journal of haematology·2025
Same author

Ventilator-Assisted Preoxygenation for Patients With Diabetic Ketoacidosis: A Novel Case Series.

Air medical journal·2025
Same author

Proteasome Inhibition Enhances Lysosome-mediated Targeted Protein Degradation.

bioRxiv : the preprint server for biology·2025
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
Same journal

State-dependent neurotensin modulation in the brain: From network dynamics to pharmacological opportunity.

Current opinion in pharmacology·2026
See all related articles

Cyclin-dependent kinase (CDK) inhibitors like flavopiridol show promise in cancer therapy by halting cell-cycle progression and inducing cancer cell death. Further research into selective CDK inhibitors is ongoing for next-generation cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cell-cycle dysregulation is a hallmark of cancer.
  • Cyclin-dependent kinase (CDK) inhibitors, such as flavopiridol, are investigated for cancer therapy.
  • These inhibitors affect cell-cycle progression and induce cell death.

Purpose of the Study:

  • To explore the mechanisms of action of CDK inhibitors, including flavopiridol.
  • To investigate the potential of CDK inhibitors in combination therapies for cancer.
  • To highlight the ongoing development of novel CDK inhibitors for antitumor applications.

Main Methods:

  • Review of existing literature on CDK inhibitors and their effects.
  • Analysis of flavopiridol's mechanisms, including transcriptional interference and apoptosis induction.

Related Experiment Videos

  • Examination of preclinical data on combination therapies involving CDK inhibitors.

    • Main Results:

    • Flavopiridol interferes with transcription, likely by disrupting the P-TEFb complex (CDK9/cyclin T).
    • Flavopiridol induces apoptosis, potentially via downregulating anti-apoptotic proteins.
    • Combination of CDK inhibitors with other agents enhances neoplastic cell death in preclinical models.

    Conclusions:

    • CDK inhibitors exhibit multifaceted anticancer activities beyond cell-cycle inhibition.
    • Targeting specific CDKs offers a promising strategy for developing new antineoplastic drugs.
    • CDK inhibitors are expected to remain a significant area of interest in cancer research and therapy.